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Abstract
Background:  We  investigated  the  effects  of  a  novel  method  of  anesthesia  combining  propo-
fol and  volatile  anesthesia  on  the  incidence  of  postoperative  nausea  and  vomiting  in  patients
undergoing  laparoscopic  gynecological  surgery.
Methods:  Patients  were  randomly  divided  into  three  groups:  those  maintained  with  sevoﬂurane
(Group S,  n  =  42),  propofol  (Group  P,  n  =  42),  or  combined  propofol  and  sevoﬂurane  (Group  PS,
n =  42).  We  assessed  complete  response  (no  postoperative  nausea  and  vomiting  and  no  rescue
antiemetic  use),  incidence  of  nausea  and  vomiting,  nausea  severity  score,  vomiting  frequency,
rescue antiemetic  use,  and  postoperative  pain  at  2 and  24  h  after  surgery.
Results: The  number  of  patients  who  exhibited  a  complete  response  was  greater  in  Groups  P  and
PS than  in  Group  S  at  0--2  h  (74%,  76%  and  43%,  respectively,  p  =  0.001)  and  0--24  h  (71%,  76%  and
38%, respectively,  p  <  0.0005).  The  incidence  of  nausea  at  0--2  h  (Group  S  =  57%,  Group  P  =  26%
and Group  PS  =  21%,  p  =  0.001)  and  0--24  h  (Group  S  =  62%,  Group  P  =  29%  and  Group  PS  =  21%,
p <  0.0005)  was  also  signiﬁcantly  different  among  groups.  However,  there  were  no  signiﬁcant
differences  among  groups  in  the  incidence  or  frequency  of  vomiting  or  rescue  antiemetic  use
at 0--24  h.
Conclusion:  Combined  propofol  and  volatile  anesthesia  during  laparoscopic  gynecological
surgery effectively  decreases  the  incidence  of  postoperative  nausea.  We  term  this  novel  method
of anesthesia  ‘‘combined  intravenous-volatile  anesthesia  (CIVA)’’.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved. Presented in part at the 57th Annual Meeting of the Japanese Society of Anesthesiologists, Fukuoka, Japan, 3-5 June 2010.
∗ Corresponding author. Present address: Department of Anesthesiology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
E-mail: hir.kawano@gmail.com (H. Kawano).
ttp://dx.doi.org/10.1016/j.bjane.2014.07.005
104-0014/© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
Combined  propofol  and  volatile  anesthesia  decreases  postoperative  nausea  13
PALAVRAS-CHAVE
Náusea  e  vômito
pós-operatórios;
Propofol;
Sevoﬂurano;
Anestesia  geral;
Laparoscopia
Efeitos  de  um  novo  método  de  anestesia  combinando  propofol  e  anestesia  volátil
sobre  a  incidência  de  náusea  e  vômito  no  pós-operatório  em  pacientes  submetidas  à
laparoscopia  ginecológica
Resumo
Justiﬁcativa:  Investigamos  os  efeitos  de  um  novo  método  de  anestesia,  combinando  propofol  e
anestesia  volátil,  sobre  a  incidência  de  náusea  e  vômito  no  período  pós-operatório  de  pacientes
submetidas  à  laparoscopia  ginecológica.
Métodos:  As  pacientes  foram  randomicamente  divididas  em  três  grupos:  manutenc¸ão  com
sevoﬂurano  (Grupo  S,  n  =  42),  com  propofol  (Grupo  P,  n  =  42)  ou  com  a  combinac¸ão  de  propofol
e sevoﬂurano  (Grupo  PS,  n  =  42).  Avaliamos  as  respostas  completas  (sem  náusea  e  vômito  no
pós-operatório  e  sem  uso  de  antiemético  de  resgate),  incidência  de  náusea  e  vômito,  escore
de gravidade  da  náusea,  freqüência  de  vômitos,  uso  de  antiemético  de  resgate  e  dor  no  pós-
operatório  em  2  e  24  h  após  a  cirurgia.
Resultados:  O  número  de  doentes  que  apresentou  uma  resposta  completa  foi  maior  nos  grupos  P
e PS  que  no  Grupo  S  em  0-2  h  (74%,  76%  e  43%,  respectivamente,  p  =  0,001)  e  0-24  h  (71%,  a  76%  e
38%, respectivamente,  p  <  0,0005).  A  incidência  de  náusea  em  0-2  h  (Grupo  S  =  57%,  Grupo  P  =  26%
e Grupo  PS  =  21%,  p  =  0,001)  e  0-24  h  (Grupo  S  =  62%,  Grupo  P  =  29%  e  grupo  PS  =  21%,  p  <  0,0005)
também  foi  signiﬁcativamente  diferente  entre  os  grupos.  Porém,  não  houve  diferenc¸a  signiﬁca-
tiva entre  os  grupos  em  relac¸ão  à  incidência  ou  frequência  de  vômitos  ou  uso  de  antiemético
de resgate  em  0-24  h.
Conclusão:  A  combinac¸ão  de  propofol  e  anestesia  volátil  durante  a  laparoscopia  ginecológica
efetivamente  diminui  a  incidência  de  náusea  no  pós-operatório.  Denominamos  este  novo  método
de anestesia  ‘‘anestesia  combinada  intravenosa  volátil  (ACIV)’’.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Volatile  anesthetics  exert  cardioprotective  effects  medi-
ated  by  the  activation  of  adenosine  triphosphate-sensitive
potassium  (KATP)  channels  in  cardiac  myocytes.1,2 They  also
affect  coronary  vasodilation  by  activating  KATP  channels
in  vascular  smooth  muscle  cells.3,4 Therefore,  the  use  of
volatile  anesthetics  for  clinical  anesthesia  may  be  beneﬁcial
in  prevention  of  coronary  artery  disease.
Total  intravenous  anesthesia  (TIVA)  with  propofol  also
has  many  advantages.  It  decreases  the  incidence  of  postop-
erative  nausea  and  vomiting  (PONV),5,6 decreases  cerebral
blood  ﬂow  and  intracranial  pressure,7 and  attenuates  post-
operative  pain8 and  neuroendocrine  stress  response.9
Because  of  these  beneﬁts  combined  with  the  rapid  onset
and  cessation  of  action,  both  volatile  anesthetics  and  propo-
fol  are  extensively  used  for  clinical  anesthesia.
We  hypothesized  that  a  novel  method  of  anesthesia
combining  propofol  and  volatile  anesthesia  can  provide  the
beneﬁts  of  both  while  decreasing  the  disadvantages  of  each
anesthetic.  In  this  study,  we  investigated  the  effects  of
combined  propofol  and  volatile  anesthesia  on  the  incidence
of  PONV  in  patients  undergoing  laparoscopic  gynecological
surgery.
Materials and methods
After  obtaining  approval  for  this  study  from  the  Ethics  Com-
mittee  on  Human  Studies  of  Tokushima  University  Hospital,
written  informed  consent  was  obtained  from  all  patients.
All  patients  were  scheduled  for  elective  laparoscopic
(
a
Synecological  surgery  (removal  of  ovarian  tumors  and  cysts,
dhesiolysis,  myomectomy,  salpingostomy,  ovarian  drilling
nd  oophorectomy)  under  general  endotracheal  anesthesia,
ith  an  American  Society  of  Anesthesiologists  (ASA)  physi-
al  status  of  I  and  II.  The  study’s  exclusion  criteria  were  as
ollows:  obesity  (body  mass  index  >33  kg/m2);  neurological,
enal,  or  liver  disease;  and  the  use  of  drugs  with  antiemetic
roperties,  including  corticosteroids.  Risk  factors  associated
ith  PONV  were  recorded.
Patients  were  randomly  assigned  to  one  of  the  following
hree  groups  by  the  sealed  envelope  method:  those  main-
ained  with  sevoﬂurane  (Group  S),  those  maintained  with
ropofol  (Group  P),  and  those  maintained  with  combined
ropofol  and  sevoﬂurane  (Group  PS).
No  preanesthetic  medication  was  administered.  All
atients  were  monitored  by  electrocardiography,  noninva-
ive  arterial  blood  pressure  measurement,  pulse  oximetry,
apnography,  and  the  bispectral  index  (BIS)  monitoring.  No
asogastric  tubes  were  inserted.  General  anesthesia  was
nduced  with  intravenous  remifentanil,  thiamylal  (Group  S)
r  propofol  (Groups  P  and  PS)  and  rocuronium.  Anesthesia
as  maintained  with  remifentanil  and  sevoﬂurane,  propofol,
r  combined  propofol  and  sevoﬂurane  in  2:1  air  and  oxygen.
In  Group  S,  anesthesia  was  maintained  with  sevoﬂurane
end-tidal  concentration  approximately  1  minimum  alveolar
oncentration).  In  Group  P,  anesthesia  was  maintained
ith  an  infusion  of  propofol  (4--8  mg/kg/h).  In  Group
S,  anesthesia  was  maintained  with  combined  propofol
2  mg/kg/h)  and  sevoﬂurane  (end-tidal  concentration
pproximately  0.5  minimum  alveolar  concentrations).
evoﬂurane  concentration  (Group  S)  and  propofol  infusion
14  H.  Kawano  et  al.
Table  1  Patient  demographics.
Group  S  (n  =  42)  Group  P  (n  =  42)  Group  PS  (n  =  42)
Age  (years) 38.9  ±  13.0 37.5  ±  13.0  40.0  ±  13.3
Height (cm)  157.6  ±  5.0  156.4  ±  5.1  157.5  ±  5.9
Weight (kg)  53.8  ±  6.9  51.8  ±  8.2  53.6  ±  9.6
MABP at  admittance  (mmHg)  94.9  ±  15.5  97.8  ±  14.6  92.9  ±  14.2
ASA physical  status  (I/II)  30/12  31/11  30/12
Smoking (n)  6  4  8
History motion  sickness  and/or  PONV  (n)  17  14  15
Phase of  menstrual  cycle  (n)
Follicular  17  16  17
Luteal 18  20  15
Postmenopause 7  6  10
MABP, mean arterial blood pressure.
Data presented as mean ± SD or number of patients. Anesthesia was maintained with sevoﬂurane (Group S), propofol (Group P), or
r
v
s
r
a
w
a
a
s
A
w
b
o
n
A
a
u
e
1
a
z
i
p
2
o
l
a
d
t
I
b
t
a
r
a
d
s
R
O
w
p
t
w
o
(
i
s
s
ﬂ
a
i
s
t
G
w
a
w
H
a
r
p
c
S
n
G
t
o
ocombined propofol and sevoﬂurane (Group PS).
ates  (Group  P)  were  titrated  to  achieve  a  target  BIS
alue  of  40--60.  In  Group  PS,  propofol  infusion  rate  and
evoﬂurane  concentration  were  ﬁxed.
Intraoperative  analgesia  was  performed  by  titrating
emifentanil  infusion  at  the  discretion  of  the  attending
nesthesiologist.  Neuromuscular  blockade  was  maintained
ith  intermittent  rocuronium.  Ringer’s  acetate  solution  was
dministered  at  10  mL/kg/h  for  the  ﬁrst  hour  of  anesthesia
nd  at  5  mL/kg/h  for  all  subsequent  hours.  Before  the  end  of
urgery,  all  patients  received  ﬂurbiprofen  axetil  (1  mg/kg).
t  the  end  of  surgery,  neuromuscular  blockade  was  reversed
ith  atropine  (0.5  mg)  and  neostigmine  (1  mg).
The  incidence  and  severity  of  PONV  were  assessed  by
linded  observers  at  2  and  24  h  after  surgery.  The  severity
f  nausea  was  recorded  using  the  following  scale:  no
ausea,  mild  nausea,  moderate  nausea,  and  severe  nausea.
 complete  response  was  deﬁned  as  no  PONV  and  no  rescue
ntiemetic  use.  Intravenous  metoclopramide  (10  mg)  was
sed  as  the  rescue  antiemetic.  Postoperative  pain  was
valuated  using  a  numerical  rating  scale  (0  =  no  pain  to
0  =  maximal  pain).  When  a  patient  requested  analgesia,
 diclofenac  suppository  (25  mg)  or  intramuscular  penta-
ocine  (15  mg)  was  administered.  The  0--2  h  and  2--24  h
ntervals  were  deﬁned  as  early  and  late,  respectively.  The
rimary  end  point  was  the  complete  response  rate  within
4  h  of  surgery.
A  previous  study10 reported  a  cumulative  PONV  incidence
f  70%  at  24  h  in  patients  undergoing  laparoscopic  gyneco-
ogical  surgery.  The  sample  size  was  determined  by  power
nalysis  to  provide  a  power  of  0.8  to  detect  a  35%  absolute
ecrease  in  the  cumulative  PONV  incidence  (˛  =  0.05).  Sta-
istical  analysis  was  performed  with  SPSS® version  18  (SPSS
nc.,  Chicago,  IL,  USA).  Continuous  variables  were  compared
y  one-way  analysis  of  variance,  with  Bonferroni  post  hoc
ests  for  multiple  comparisons.  Categorical  variables  were
nalyzed  using  the  2 or  Fisher’s  exact  tests,  with  cor-
ection  for  multiple  comparisons  where  appropriate.  Data
re  expressed  as  number  of  patients  or  mean  ±  standard
eviation.  A  p-value  of  <0.05  was  considered  statistically
igniﬁcant.
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f  130  patients,  four  were  excluded  from  this  analysis:  two
ho  converted  to  laparotomy  and  two  violated  the  study
rotocol.  Therefore,  42  patients  were  randomly  allocated
o  Group  S,  42  to  Group  P,  and  42  to  Group  PS.
Demographic  data  were  similar  with  respect  to  age,
eight,  height,  ASA  physical  status,  smoking  history,  history
f  motion  sickness  and/or  PONV,  and  menstrual  cycle  phase
Table  1).  Similarly,  there  were  no  signiﬁcant  differences  in
ntraoperative  variables,  including  the  duration  of  anesthe-
ia  and  surgery,  total  doses  of  remifentanil  and  rocuronium,
urgery  type,  temperature,  blood  loss,  and  intravascular
uid  volume  (Table  2).
A  complete  response  at  24  h  (primary  end  point)  was
chieved  in  38%  patients  in  Group  S,  71%  in  Group  P  and  76%
n  Group  PS  (p  <  0.0005)  (Table  3).  Groups  P  and  PS  differed
igniﬁcantly  from  Group  S  (p  =  0.012  and  <  0.002,  respec-
ively),  but  no  signiﬁcant  difference  was  evident  between
roups  P  and  PS  (Table  3).  The  incidence  of  nausea  at  24  h
as  also  signiﬁcantly  different  (Group  S  =  62%,  Group  P  = 29%
nd  Group  PS  =  21%,  p  <  0.0005).  The  signiﬁcant  nausea  rate
as  also  lower  in  Group  P  and  PS  than  in  Group  S  (p  =  0.003).
owever,  there  were  no  statistically  signiﬁcant  differences
mong  groups  in  the  incidence  or  frequency  of  vomiting  or
escue  antiemetic  use  at  24  h  (Table  3).
In  the  early  postoperative  period,  the  proportion  of
atients  who  experienced  a  complete  response  was  signiﬁ-
antly  higher  in  Groups  P  (74%)  and  PS  (76%)  than  in  Group
 (43%)  (p  =  0.001).  The  incidence  of  nausea  was  also  sig-
iﬁcantly  lower  in  Groups  P  (26%)  and  PS  (21%)  than  in
roup  S  (57%)  (p  =  0.001).  However,  there  were  no  statis-
ically  signiﬁcant  differences  among  groups  in  the  incidence
r  frequency  of  vomiting  at  this  time  (Table  3).
In  the  late  postoperative  period,  although  the  incidence
f  nausea  was  lower  in  Groups  P  (12%)  and  PS  (10%)  than  in
roup  S (26%),  the  difference  was  not  statistically  signiﬁcant
p  =  0.078).  The  proportion  of  patients  exhibiting  a  complete
esponse,  the  incidence  and  frequency  of  vomiting,  severity
f  nausea,  and  rescue  antiemetic  use  did  not  differ  among
roups  during  at  this  time  (Table  3).
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Table  2  Surgery/anesthesia-related  parameters.
Group  S  (n  =  42)  Group  P  (n  =  42)  Group  PS  (n  =  42)
Duration  of  anesthesia  (min) 171.2  ±  58.6 167.9  ±  67.1  155.5  ±  48.7
Duration of  surgery  (min)  124.7  ±  54.5  122.1  ±  65.3  111.5  ±  48.7
Anesthetics
Remifentanil (mg)  3.082  ±  1.884  3.197  ±  1.856  3.055  ±  1.420
Rocuronium (mg)  54.8  ±  13.2  53.1  ±  13.4  50.6  ±  13.0
Type of  surgery  (n)
Ovarian  cystectomy/tumorectomy  31  24  32
Adhesiolysis 2  5  2
Myomectomy 6  9  3
Salpingostomy  1  0  2
Ovarian drilling  1  0  1
Oophorectomy  1  4  2
Temperature (◦C)  36.6  ±  0.4  36.4  ±  0.4  36.6  ±  0.6
Blood loss  (mL)  28.8  ±  54.5  65.4  ±  142.7  31.4  ±  58.8
Fluid volume  (mL) 1059.0  ±  312.3  1109.8  ±  440.9  1036.0  ±  341.1
Data presented as mean ± SD or number of patients.
Anesthesia was maintained with sevoﬂurane (Group S), propofol (Group P), or combined propofol and sevoﬂurane (Group PS).
Table  3  Incidence  of  postoperative  nausea  and  vomiting.
Group  S  (n  =  42)  Group  P  (n  =  42)  Group  PS  (n  =  42)  p-Value
0--2  postoperative  hours
Nausea  24  (57)  11  (26)b 9  (21)b 0.001a
Signiﬁcant  nausea  (moderate  or  severe)  16  (38)  7  (17)  3  (7)b 0.001a
Vomiting  4  (10)  5  (12)  3  (7)  0.759
Vomiting episodes  in  patients  who  vomited  2.3  ±  1.5  1.2  ±  0.4  2  ±  1.7  0.155
Postoperative  nausea  and/or  vomiting  24  (57)  11  (26)b 9  (21)b 0.001a
Rescue  antiemetic  8  (19)  1  (2)  2  (5)  0.014a
Complete  response  18  (43)  31  (74)b 33  (76)b 0.001a
2--24  postoperative  hours
Nausea  11  (26)  5  (12)  4  (10)  0.078
Signiﬁcant nausea  (moderate  or  severe)  1  (2)  3  (7)  2  (5)  0.592
Vomiting 2  (5)  4  (10)  2  (5)  0.586
Vomiting episodes  in  patients  who  vomited  1.5  ±  0.7  2.3  ±  1.5  3  ±  0  0.530
Postoperative  nausea  and/or  vomiting  11  (26)  5  (12)  4  (10)  0.078
Rescue antiemetic  2  (5)  3  (7)  0  (0)  0.233
Complete response  31  (74)  36  (86)  38  (90)  0.108
0--24 postoperative  hours
Nausea  26  (62)  12  (29)b 9  (21)b <0.0005a
Signiﬁcant  nausea  (moderate  or  severe)  17  (40)  8  (19)  4  (10)b 0.003a
Vomiting  4  (10)  6  (14)  3  (7)  0.549
Vomiting episodes  in  patients  who  vomited  3  ±  2.2  2.5  ±  1.2  4  ±  3  0.651
Postoperative  nausea  and/or  vomiting  26  (62)  12  (29)b 9  (21)b <0.0005a
Rescue  antiemetic  9  (21)  4  (10)  2  (5)  0.052
Complete response  16  (38)  30  (71)b 33  (76)b <0.0005a
Data presented as mean ± SD or number of patients (%).
Anesthesia was maintained with sevoﬂurane (Group S), propofol (Group P), or combined propofol and sevoﬂurane (Group PS).
a Statistically signiﬁcant difference (p < 0.05).
b Statistically signiﬁcant difference from Group S (p < 0.05).
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Table  4  Postoperative  pain  data.
Group  S  (n  =  42)  Group  P  (n  =  42)  Group  PS  (n  =  42)
Numerical  rating  scale  (0--10)
Postoperative  at
2  h  6.4  ±  2.5  5.6  ±  2.3  5.9  ±  3.0
24 h  4.1  ±  2.3  3.7  ±  1.9  3.8  ±  2.4
Postoperative  diclofenac  sodium  (mg)  17.3  ±  18.7  16.7  ±  18.0  17.9  ±  18.5
Postoperative  pentazocine  (mg)  7.9  ±  8.9  8.6  ±  13.7  4.6  ±  7.4
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aData presented as mean ± SD.
Anesthesia was maintained with sevoﬂurane (Group S), propofol (
There  was  no  difference  among  groups  in  the  numerical
ating  scale  or  analgesia  use  (Table  4).  No  patients  reported
ntraoperative  awareness.
iscussion
his  study  demonstrates  that  the  use  of  combined  propofol
nd  sevoﬂurane  anesthesia  during  laparoscopic  gynecologi-
al  surgery  decreases  PONV  incidence.  This  is  the  ﬁrst  study,
s  per  our  knowledge,  to  assess  the  effects  of  combined
ropofol  and  volatile  anesthesia  on  PONV  incidence.
The  use  of  volatile  anesthetics  such  as  isoﬂurane
nd  sevoﬂurane  has  many  beneﬁts.  The  representative
eneﬁcial  effect  is  cardioprotection.  Volatile  anesthet-
cs  have  been  shown  to  protect  the  myocardium  against
yocardial  ischemia  and  reperfusion  injury  through  a sig-
al  transduction  pathway  that  includes  protein  kinase
 and  mitochondrial  and  sarcolemmal  KATP  channels.1,2
eportedly,3,4 volatile  anesthetics  also  cause  coronary
asodilatation  by  activating  vascular  KATP  channels.  Ran-
omized  clinical  trials  in  patients  undergoing  coronary
rtery  surgery  have  demonstrated  that  volatile  anesthetics
ecrease  troponin  release,  the  duration  of  intensive  care
nit  stay,  and  the  incidence  of  late  cardiac  events  and
nhance  left  ventricular  function.11 On  the  basis  of  these
rials,  the  American  College  of  Cardiology/American  Heart
ssociation  2007  guidelines  on  perioperative  cardiovascular
valuation  and  care  for  noncardiac  surgery11 recommend  the
se  of  volatile  anesthetic  agents  during  noncardiac  surgery
or  maintenance  of  general  anesthesia  in  hemodynamically
table  patients  at  risk  for  myocardial  ischemia  (Class  IIa,
evel  of  evidence  B).  The  additional  beneﬁts  of  volatile  anes-
hesia  include  a  lower  incidence  of  intraoperative  awareness
uring  general  anesthesia12 and  a  bronchodilatory  effect.13
TIVA  with  propofol  is  associated  with  a  lower  PONV
ncidence.5,6 In  addition,  TIVA  has  many  advantages  over
olatile  anesthesia.  Several  studies7 have  shown  that  propo-
ol  causes  a  dose-related  decrease  in  cerebral  blood  ﬂow,
he  rate  of  cerebral  metabolism  of  oxygen,  and  intracra-
ial  pressure.  Animal  studies14 have  demonstrated  that
olatile  anesthetics  inhibit  hypoxic  pulmonary  vasoconstric-
ion  (HPV)  in  a  dose-dependent  manner,  although  propofol
oes  not  seem  to  affect  HPV.15 Although  it  remains  contro-
ersial  whether  propofol  can  induce  malignant  hyperthermia
MH),16 Sumitani  et  al.17 reported  a  relatively  low  preva-
ence  of  MH  in  propofol  users.  Previous  studies8 have
emonstrated  that  patients  anesthetized  with  propofol
A
8
a
2p P), or combined propofol and sevoﬂurane (Group PS).
xperience  less  pain  than  those  anesthetized  with  volatile
nesthetics.  Furthermore,  TIVA  was  shown  to  be  more
ffective  in  inhibiting  the  neuroendocrine  stress  response
ompared  with  volatile  anesthesia.9 Propofol  may  also  pre-
ent  tissue  damage  resulting  from  oxidative  stress18 through
ts  antioxidant  properties.19
Propofol  and  volatile  anesthetics  such  as  sevoﬂurane
nd  desﬂurane  are  extensively  used  for  clinical  anesthe-
ia  because  of  the  rapid  onset  and  cessation  of  action.
he  use  of  each  anesthetic  has  both  advantages  and  dis-
dvantages.  We  developed  a  novel  method  of  anesthesia
ombining  propofol  and  volatile  anesthesia  to  receive  the
eneﬁts  and  decrease  the  disadvantages  of  each  anesthetic.
owever,  this  was  just  a  hypothesis,  and  the  actual  effects
f  combination  remain  unknown.  Therefore,  we  evaluated
he  effects  of  combined  propofol  and  volatile  anesthesia  on
ONV  incidence  in  patients  undergoing  laparoscopic  gyne-
ological  surgery.
The  results  of  this  study  showed  that  the  use  of  combined
ropofol  and  volatile  anesthesia  during  laparoscopic  gyneco-
ogical  surgery  caused  a  66%  reduction  in  PONV  (from  62%  to
1%),  an  effect  that  was  more  pronounced  in  the  early  post-
perative  period.  Surprisingly,  this  effect  is  comparable  with
hat  of  TIVA  with  propofol  (a  66%  decrease  in  Group  PS  versus
 53%  decrease  in  Group  P).  The  PONV  incidence  in  Group  S
62%)  was  similar  to  the  previously  reported  PONV  incidence
ndergoing  laparoscopic  gynecological  surgery.10,20
Patients  in  Group  PS  received  signiﬁcantly  smaller  doses
f  sevoﬂurane  during  anesthesia,  which  may  explain  the
ecreased  PONV  incidence.  Apfel  et  al.21 reported  that  the
egree  of  exposure  to  volatile  anesthetics  is  the  primary
ause  of  PONV  in  the  early  postoperative  period.  Another
eason  for  the  decreased  PONV  incidence  could  be  the
ntiemetic  effects  of  propofol.  The  antiemetic  properties  of
ropofol  were  ﬁrst  demonstrated  by  Borgeat  et  al.22 and  sub-
equently  by  several  other  authors.23 However,  its  precise
echanism  of  action  remains  unclear.  Propofol  may  act  as  a
opamine  receptor  antagonist.24 It  has  also  been  shown  to
ossess  a  weak  antagonistic  effect  against  serotonin.  How-
ver,  the  precise  mechanism  by  which  propofol  exerts  its
ntiemetic  effects  remain  undetermined.  Reportedly,25 the
ffect  is  associated  with  a  deﬁned  plasma  concentration
ange;  the  plasma  propofol  concentration  associated  with
 50%  decrease  in  nausea  scores  was  found  to  be  343  ng/mL.
ccording  to  the  pharmacokinetic  simulation  (TIVA  trainer
,  Frank  Engbers,  Leiden,  The  Netherlands),  155  min  after
n  induction  dose  of  1.5  mg/kg  and  maintenance  with
 mg/kg/h,  the  plasma  concentration  of  propofol  is  1 g/mL.
erat
1
1
1
1
1
1
1
1
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1Combined  propofol  and  volatile  anesthesia  decreases  postop
Simulation  data  also  demonstrate  that  the  plasma  propofol
concentration  drops  below  350  ng/mL  within  approximately
170  min  of  the  end  of  infusion.  These  simulation  data  sug-
gest  that  the  plasma  concentration  of  propofol  used  in  our
method  will  above  the  range  effective  for  antiemesis  until
approximately  170  min  after  the  end  of  surgery.  This  prob-
ably  explains  why  patients  in  Group  PS  exhibited  a  lower
incidence  of  PONV,  particularly  in  the  early  postoperative
period.
Limitations  of  the  study
Our  study  has  some  limitations.  First,  there  is  increasing
consensus  that  better  PONV  prophylaxis  can  be  achieved
through  the  use  of  a  combination  of  agents  acting  on  dif-
ferent  receptors,  considering  that  multiple  receptors  are
involved  in  the  etiology  of  PONV.  In  high-risk  patients,  a  mul-
timodal  approach  to  prevent  PONV  has  been  recommended.
However,  we  did  not  administer  any  prophylactic  antiemetic
or  combined  agents  to  prevent  PONV.  This  is  because
we  wanted  to  investigate  the  baseline  risk,  which  could
have  been  masked  by  prophylactic  antiemetic.  Decreasing
the  baseline  risk  has  been  recommended26 because  it  can
signiﬁcantly  decrease  PONV  incidence.27,28 In  addition,  pro-
phylactic  antiemetic  are  associated  with  an  increase  in  both
costs  and  adverse  effects.29,30 Therefore,  we  considered  it
important  to  study  the  pure  incidence  of  PONV  for  each
method  of  anesthesia.  Second,  only  one  combination  of
propofol  infusion  rate  and  sevoﬂurane  concentration  was
studied,  and  the  effects  of  other  combinations  were  not
assessed  in  this  study.  Therefore,  the  optimal  combina-
tion  of  propofol  infusion  rate  and  sevoﬂurane  concentration
remains  to  be  determined.
Conclusions
In  conclusion,  combined  propofol  and  volatile  anesthe-
sia  during  laparoscopic  gynecological  surgery  effectively
decreases  PONV  incidence  in  the  absence  of  prophylac-
tic  antiemetic.  Although  further  experimental  research  is
required  to  clarify  its  efﬁcacy  in  a  clinical  context,  we
believe  that  combined  propofol  and  volatile  anesthesia
offers  potential  clinical  beneﬁts.  We  term  this  novel  method
of  anesthesia  ‘‘combined  intravenous-volatile  anesthesia
(CIVA)’’.
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